Dr. Harald Hasselmann appointed as new managing director of Eckert & Ziegler BEBIG
2015-09-03 / As part of the restructuring measures at medical technology company Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB), the Board of Directors has appointed business administration expert Dr. Harald Hasselmann (aged 48) as the new commercial managing director for sales and finances. With effect from October 1, 2015 he will be a member of the management team and head the company together with Dr. Edgar Löffler, a medical physicist, who is responsible for the irradiation equipment manufacturer’s technical operations. Abel Luzuriaga, who has been managing director for sales and marketing at Eckert & Ziegler BEBIG since 2012, is leaving the company of his own accord.
Harald Hasselmann, born in Hamburg, has gained extensive experience at various international pharmaceutical companies. He was head of controlling for Europe at Bayer Pharma, managing director at Schering’s Hungarian subsidiary and director of the Berlin-based biotech company metaGen. He has held various positions in large and medium-sized healthcare companies and has an excellent track record in sales, controlling and implementing restructuring measures.
“With Dr. Hasselmann we have won an ideal industry expert who will serve to substantially enhance our company’s skills and capabilities, especially with regard to implementing our restructuring strategy,” explains Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG SA. “I am looking forward to the new challenges at Eckert & Ziegler BEBIG. The emphasis will be on the segment’s profitability and growth at an international level,” added Dr. Harald Hasselmann.
The Board of Directors would like to thank Mr. Luzuriaga for his dedication and in particular for his involvement in expanding the market for tumor irradiation equipment.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy. The company headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents, to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 180 people. The company has been listed on the Euronext stock exchange since April 1997.
Eckert & Ziegler BEBIG SA
Att. Investor Relations & Communications
Tel: +32 64 520 808
Fax: +32 64 520 801